Targeting survivin in cancer therapy

Marzia Pennati, Marco Folini, Nadia Zaffaroni

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background: Survivin is a structurally unique member of the inhibitor of apoptosis protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Owing to its massive upregulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target. Objective: The purpose of this review is to define the potential of survivin as a therapeutic target for new anticancer interventions. Methods: The literature dealing with the therapeutic targeting of survivin has been carefully reviewed. Results/conclusion: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced tumor growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models. Moreover, the first survivin inhibitors are being currently evaluated in clinical settings.

Original languageEnglish
Pages (from-to)463-476
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Tumors
Neoplasms
Cells
Inhibitor of Apoptosis Proteins
Therapeutics
Cell Division
Apoptosis
Radiation
Up-Regulation
Down-Regulation
Pharmaceutical Preparations
Growth

Keywords

  • Antisense oligonucleotides
  • Apoptosis
  • Cell cyde
  • Dominant negative mutants
  • Human cancers
  • Inhibitor of apoptosis proteins
  • Ribozymes
  • Small interfering RNAs
  • Survivin

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Targeting survivin in cancer therapy. / Pennati, Marzia; Folini, Marco; Zaffaroni, Nadia.

In: Expert Opinion on Therapeutic Targets, Vol. 12, No. 4, 04.2008, p. 463-476.

Research output: Contribution to journalArticle

@article{28dcd2f1aaa141d9a0f45638d0327564,
title = "Targeting survivin in cancer therapy",
abstract = "Background: Survivin is a structurally unique member of the inhibitor of apoptosis protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Owing to its massive upregulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target. Objective: The purpose of this review is to define the potential of survivin as a therapeutic target for new anticancer interventions. Methods: The literature dealing with the therapeutic targeting of survivin has been carefully reviewed. Results/conclusion: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced tumor growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models. Moreover, the first survivin inhibitors are being currently evaluated in clinical settings.",
keywords = "Antisense oligonucleotides, Apoptosis, Cell cyde, Dominant negative mutants, Human cancers, Inhibitor of apoptosis proteins, Ribozymes, Small interfering RNAs, Survivin",
author = "Marzia Pennati and Marco Folini and Nadia Zaffaroni",
year = "2008",
month = "4",
doi = "10.1517/14728222.12.4.463",
language = "English",
volume = "12",
pages = "463--476",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Targeting survivin in cancer therapy

AU - Pennati, Marzia

AU - Folini, Marco

AU - Zaffaroni, Nadia

PY - 2008/4

Y1 - 2008/4

N2 - Background: Survivin is a structurally unique member of the inhibitor of apoptosis protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Owing to its massive upregulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target. Objective: The purpose of this review is to define the potential of survivin as a therapeutic target for new anticancer interventions. Methods: The literature dealing with the therapeutic targeting of survivin has been carefully reviewed. Results/conclusion: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced tumor growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models. Moreover, the first survivin inhibitors are being currently evaluated in clinical settings.

AB - Background: Survivin is a structurally unique member of the inhibitor of apoptosis protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Owing to its massive upregulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target. Objective: The purpose of this review is to define the potential of survivin as a therapeutic target for new anticancer interventions. Methods: The literature dealing with the therapeutic targeting of survivin has been carefully reviewed. Results/conclusion: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced tumor growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models. Moreover, the first survivin inhibitors are being currently evaluated in clinical settings.

KW - Antisense oligonucleotides

KW - Apoptosis

KW - Cell cyde

KW - Dominant negative mutants

KW - Human cancers

KW - Inhibitor of apoptosis proteins

KW - Ribozymes

KW - Small interfering RNAs

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=42149092791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149092791&partnerID=8YFLogxK

U2 - 10.1517/14728222.12.4.463

DO - 10.1517/14728222.12.4.463

M3 - Article

C2 - 18348682

AN - SCOPUS:42149092791

VL - 12

SP - 463

EP - 476

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 4

ER -